Market Research Hub

New Research Study on Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC Review, H2 2017

Report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.


Albany, NY -- (SBWIRE) -- 10/10/2017 -- Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC is developed by companies and universities. The pipeline target involves 37 molecules, of which nearly 29 are developed by companies, and the rest of the molecules are developed by universities. A new report titled "Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC Review, H2 2017" offers research and analysis on the pipeline of Histone Deacetylase 6, offering information on the drugs at various phases of development. The research report has been submitted to the vast repository of Market Research Hub (MRH).

Request Free Sample Report:

According to the report, molecules 4, 3, 14, and 8 – developed by the companies – are in Phase II, Phase I, Preclinical, and Discovery. Numerous therapy areas discussed in the report include (but are not limited to) oncology, genetic disorders, toxicology, breast cancer, non-small cell lung cancer, autoimmune disorders, bile duct cancer, colon cancer, diabetic neuropathic pain, liver cancer, soft tissue sarcoma, prostate cancer, and Parkinson's disease.

The detailed report provides information on the global landscape for Histone Deacetylase 6 (Protein Phosphatase 1 Regulatory Subunit 90 or HDAC6 or EC Readers can expect complete information on the different molecules which are in phases of development. Products that are under various stages of development, such as pre-discover and undisclosed, are also covered in the report. The report also offers valuable guidance and analysis on descriptive drug profiles, which includes R&D analysis, and collaboration details.

In a bid to offer detailed analysis to readers, the report gives insights on therapeutics development, including development by therapy area, indication, companies, and universities. The therapeutics assessment is offered on the basis of action, route of administration, and molecule type.

The completion landscape part of the report offers detailed information on the key companies involved in the development of drugs. The main companies involved in the development of drugs include Celgene Corp, Curis Inc, Kancera AB, Medivir AB, OnKure Inc, and Shuttle Pharmaceuticals LLC, and Sigma-Tau SpA.

Browse Full Report with TOC-

In addition to offering detailed competitive landscape, the report also offers insights on various product descriptions, mechanism of action, and evolving trends in regulatory landscape. The development of drugs is closely influenced by changes in regulatory atmosphere, and the report offers these insights to stakeholders.

The report has been developed after thorough primary and secondary research. The robust methodology employed in the compilation of this report ensures that readers get detailed and unbiased insights into this market.

Enquire about this Report-

About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH's expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free : 800-998-4852 (US-Canada)
Email :
Website :
Read Industry News at -